+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immune Disorders Drugs Market Research Reports

Celiac Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Celiac Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
From
From
From
From
H 4 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

H 4 Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
H 3 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

H 3 Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
H 2 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

H 2 Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
HIV Attachment Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

HIV Attachment Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
E-Selectin Inhibitor- Pipeline Insight, 2025 - Product Thumbnail Image

E-Selectin Inhibitor- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
NF-kappa B Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

NF-kappa B Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
H Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

H Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Sanfilippo Syndrome Type A (MPS IIIA) - Pipeline Insight, 2025 - Product Thumbnail Image

Sanfilippo Syndrome Type A (MPS IIIA) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Antibody-Mediated Graft Rejection - Pipeline Insight, 2025 - Product Thumbnail Image

Antibody-Mediated Graft Rejection - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Eosinophilic Disorder - Pipeline Insight, 2025 - Product Thumbnail Image

Eosinophilic Disorder - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Erythropoietic Protoporphyria - Pipeline Insight, 2025 - Product Thumbnail Image

Erythropoietic Protoporphyria - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
IgG4-Related Disease - Pipeline Insight, 2025 - Product Thumbnail Image

IgG4-Related Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Peripheral SpA - Pipeline Insight, 2025 - Product Thumbnail Image

Peripheral SpA - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Psoriasis Vulgaris- Pipeline Insight, 2025 - Product Thumbnail Image

Psoriasis Vulgaris- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
X-Linked Myotubular Myopathy (XLMTM) - Pipeline Insight, 2025 - Product Thumbnail Image

X-Linked Myotubular Myopathy (XLMTM) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Immune Disorders Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs to treat immune system disorders. These drugs are used to treat a variety of conditions, including allergies, asthma, autoimmune diseases, and cancer. Immune Disorders Drugs are designed to target specific parts of the immune system, such as cytokines, antibodies, and T-cells, to reduce inflammation and improve the body's ability to fight off infection. The Immune Disorders Drugs market is highly competitive, with many large pharmaceutical companies competing for market share. Some of the major players in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are constantly researching and developing new drugs to treat immune system disorders, as well as improving existing treatments. Show Less Read more